Clathrin therapeutic for cancer

Abstract

The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic composition, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating various types of a cancerous disease, condition, or disorder in vivo or in vitro.

In view of the foregoing, what is claimed is: 
     
         1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . (canceled) 
     
     
         21 . (canceled) 
     
     
         22 . A pharmaceutical composition for treating a disease, condition, or disorder comprising: a man made non-cage clathrin protein and has an amino acid sequence of at least 50, 60, 70, 80, or 90% sequence identity when compared to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11, and administering to a subject in need thereof the preceding protein or composition, wherein the disease, condition, or disorder comprises at least one of cancer. 
     
     
         23 . The pharmaceutical composition of  claim 22 , further comprising a man made protein that has at least 50, 60, 70, 80, or 90% sequence identity when compared to SEQ ID NO: 12 or SEQ ID NO: 13, and the preceding protein disposed adjacent to the sequence according to  claim 22 , and binding to the sequence. 
     
     
         24 . The pharmaceutical composition of  claim 22 , wherein the protein comprises multiple proteins. 
     
     
         25 . The pharmaceutical composition of  claim 22 , wherein the man made protein comprises biologically active, biologically modified, chiral, genetically modified, hybridized, isolated, chemically modified, masked, recombinant, synthetic or unmasked protein molecules, or a combination thereof. 
     
     
         26 . The pharmaceutical composition of  claim 22 , wherein the man made protein has a molecular mass of at least about 170 kilodaltons. 
     
     
         27 . The pharmaceutical composition of  claim 22 , wherein the man made protein is stable with respect to dissociation. 
     
     
         28 . The pharmaceutical composition of  claim 22 , wherein the pharmaceutical composition is formulated for any suitable route and means of administration. 
     
     
         29 . The pharmaceutical composition of  claim 28 , wherein the pharmaceutical composition is formulated as an adhesive, aerosols, a biologic, a capsule, a chemical compound, a coated, crystals, eye drops, gels, an injectable, liquids, oils, ointments, a polymer, powders, a prosthetic, salves, soft galantine capsules, a stent, a controlled release, subcutaneous, surgical, syrups, a tablet, a topical, a vapor, or a water soluble formula. 
     
     
         30 . The pharmaceutical composition of  claim 22 , further comprising a therapeutic agent. 
     
     
         31 . The pharmaceutical composition of  claim 30 , wherein the therapeutic agent is a drug for treating a disease, condition or disorder comprising at least one of cancer. 
     
     
         32 . A method for treating a disease, condition, or disorder comprising at least one of cancer of a subject, comprising administering a pharmaceutical composition according to  claim 22  to the subject. 
     
     
         33 . The method of  claim 32 , wherein treating comprises treating at least one of cell transport of the subject. 
     
     
         34 . The method of  claim 32 , wherein treating comprises treating at least one of cell signaling of the subject. 
     
     
         35 . The method of  claim 32 , wherein treating comprises treating at least one of cell trafficking of the subject. 
     
     
         36 . The method of  claim 32 , wherein treating comprises treating at least one of cell communication of the subject. 
     
     
         37 . The method of  claim 32 , wherein treating comprises treating at least one of cell regulation of the subject. 
     
     
         38 . The method of  claim 32 , wherein treating comprises treating at least one of cell growth of the subject. 
     
     
         39 . The method of  claim 32 , wherein treating comprises treating at least one of cell metabolism of the subject. 
     
     
         40 . The method of  claim 32 , wherein treating comprises treating at least one of cell DNA of the subject. 
     
     
         41 . The method of  claim 32 , wherein treating comprises treating at least one of cell RNA of the subject. 
     
     
         42 . The method of  claim 32 , wherein treating comprises treating at least one of cell growth factor of the subject. 
     
     
         43 . The method of  claim 32 , wherein treating comprises treating at least one of cell antibody of the subject. 
     
     
         44 . A method for a pharmaceutical composition for treating a disease, condition, or disorder comprising: a man made non-cage clathrin protein and has an amino acid sequence of at least 50, 60, 70, 80, or 90% sequence identity when compared to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10 or SEQ ID NO: 11, and administering to a subject in need thereof the preceding protein or composition, wherein the disease, condition, or disorder comprises at least one of cancer. 
     
     
         45 . A method for treating at least one of cancer disease, condition, or disorder, comprising formulating the composition according to  claim 22  as a supplemental drug for use by other drugs. 
     
     
         46 . A method for targeting at least one of cancer disease, condition, or disorder, comprising administering the composition to the subject according to  claim 22 .